Bamidele Ekunsanmi, MD
Internal Medicine · Rock Hill, SCNPI 1932156171
Payments from drug & device makers
What this record shows
14 manufacturers reported payments, led by Amgen at 37.3% of the total. Reporting peaked in 2024 at $3,446 and has fallen 94.3% since, to $196 in 2025.
Across 62 payments — averaging $75.03 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- Amgen$2K
- AstraZeneca$1K
- Novo Nordisk$445
- AbbVie$261
- Pfizer$180
- Viiv Healthcare Company$125
- plus $432 from 8 others
Across 14 payments — averaging $5854.42 each. Payments tied to a research study. These frequently flow through the physician to a hospital or research institution rather than to the physician personally.
- Amgen$35K
- Lexicon Pharmaceuticals, Inc.$26K
- Astrazeneca UK Limited$20K
What the payments were for
- Travel & lodging$2,32250%
- Food & beverage$2,33050%
Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| Amgen(2 entities) | 5 | $1,734 |
| AstraZeneca | 9 | $1,475 |
| Novo Nordisk | 17 | $445 |
| AbbVie | 7 | $261 |
| Pfizer | 9 | $180 |
| Viiv Healthcare Company | 1 | $125 |
| Gilead | 1 | $105 |
| Davol Inc. | 1 | $92 |
| Exact Sciences | 3 | $60 |
| Lilly USA, LLC | 3 | $57 |
| Otsuka America Pharmaceutical, Inc. | 3 | $49 |
| Lucid Diagnostics Inc. | 1 | $27 |
| Kowa Pharmaceuticals America, Inc. | 1 | $22 |
| Idorsia Pharmaceuticals US Inc | 1 | $20 |
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
How this compares
$4,652 in reported general payments places this provider in the 85th percentile of 1,498 internal medicine providers in South Carolina.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| OzempicSemaglutide | 38 | $36,462 |
| RybelsusSemaglutide | 23 | $23,575 |
| LinzessLinaclotide | 12 | $6,601 |
| Tresiba Flextouch U-100Insulin Degludec | 14 | $5,554 |
| Lantus SolostarInsulin Glargine,hum.Rec.Anlog | 18 | $1,767 |
| Hydrocodone-AcetaminophenHydrocodone/Acetaminophen | 79 | $1,728 |
| Megestrol Acetate | 13 | $1,652 |
| Oxycodone-AcetaminophenOxycodone Hcl/Acetaminophen | 44 | $1,544 |
| Clonidine | 12 | $1,301 |
| Omeprazole | 85 | $1,252 |
| Olmesartan-HydrochlorothiazideOlmesartan/Hydrochlorothiazide | 21 | $1,052 |
| Diclofenac Sodium | 75 | $1,038 |
| Pregabalin | 25 | $1,004 |
| Gabapentin | 115 | $847 |
| Amlodipine Besylate | 254 | $835 |
Paid to pharmacies, not to this prescriber.
Companies that both paid and supply prescribed drugs
These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.
| Company | Paid to this provider | Part D cost of their drugs |
|---|---|---|
| Novo NordiskOzempic, Rybelsus | $445 | $60,03761 claims |
| AbbVieLinzess | $261 | $6,60112 claims |
Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 85th percentile of 1,498 internal medicine providers in South Carolina.
Other internal medicine in Rock Hill
- Rajesh KedarRock Hill$14K
- Randolph VillamorRock Hill$13K
- John HoitinkRock Hill$12K
- Rhea HsuRock Hill$11K
- Matthew JenkinsRock Hill$11K
- Jerry BackNorth Charleston$322K
- Jan BasileCharleston$278K
- Mark PurcellGreenville$165K
- John CleekCharleston$136K
- William BunnHilton Head Island$125K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.